(NASDAQ: BVS) Bioventus's forecast annual revenue growth rate of 6.46% is forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 6.03%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.01%.
Bioventus's revenue in 2026 is $585,639,000.On average, 6 Wall Street analysts forecast BVS's revenue for 2026 to be $50,626,510,193, with the lowest BVS revenue forecast at $48,926,124,101, and the highest BVS revenue forecast at $53,262,192,897. On average, 6 Wall Street analysts forecast BVS's revenue for 2027 to be $54,038,236,302, with the lowest BVS revenue forecast at $51,436,257,981, and the highest BVS revenue forecast at $57,048,037,650.
In 2028, BVS is forecast to generate $60,048,570,293 in revenue, with the lowest revenue forecast at $55,553,248,291 and the highest revenue forecast at $67,198,112,410.